Alpha 2.0
Login Register
» Articles » PMID: 37277893

First-trimester Screening Strategies: A Balance Between Costs, Efficiency and Diagnostic Yield

Overview
Journal Prenat Diagn
Publisher Wiley
Specialty Gynecology & Obstetrics
Date 2023 Jun 5
PMID 37277893
Authors
Francesca Bardi
Karl Oliver Kagan
Caterina Maddalena Bilardo
Affiliations
Soon will be listed here.
Citing Articles

Impact of a new image enhancement technology on the nuchal translucency thickness.

Elger T, Prodan N, Bettecken K, Sonek J, Kagan K Arch Gynecol Obstet. 2025; .

PMID: 39862271 DOI: 10.1007/s00404-024-07924-1.

Performance of cell free DNA as a screening tool based on the results of first trimester screening.

Motevasselian M, Omrani M, Saleh Gargari S, Younesi S, Taheri Amin M, Saadati P Mol Cytogenet. 2024; 17(1):33.

PMID: 39707390 PMC: 11662775. DOI: 10.1186/s13039-024-00702-3.

Performance of Massive Parallel Sequencing-Based Cell-Free DNA Testing in Compromised Pregnancies.

Antolin M, Tarraso G, Sanchez M, Plaja A, Martinez-Cruz D, Xuncla M J Clin Med. 2024; 13(14).

PMID: 39064047 PMC: 11277969. DOI: 10.3390/jcm13144007.

Is Nuchal Translucency of 3.0-3.4 mm an Indication for cfDNA Testing or Microarray? - A Multicenter Retrospective Clinical Cohort Study.

Rybak-Krzyszkowska M, Madetko-Talowska A, Szewczyk K, Bik-Multanowski M, Sakowicz A, Stejskal D Fetal Diagn Ther. 2024; 51(5):453-462.

PMID: 38815555 PMC: 11446333. DOI: 10.1159/000539463.

Importance of a detailed anomaly scan after a cfDNA test indicating fetal trisomy 21, 18 or 13.

Spingler T, Sonek J, Hoopmann M, Prodan N, Jonaityte G, Elger T Arch Gynecol Obstet. 2023; 310(2):749-755.

PMID: 38091054 PMC: 11258052. DOI: 10.1007/s00404-023-07311-2.